Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.
In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated. Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23). Correspondingly, the plasma dapsone 24 h after the last dose had fallen significantly from 2.63 to 2.02 mg/l. Clofazimine did not cause change in the pharmacokinetics of dapsone. It was concluded that, although rifampicin had a considerable influence on the pharmacokinetics of dapsone, there is no reason to adjust the dose of dapsone during multidrug therapy of leprosy.
Pieters
F A
FA
Department of Biopharmaceutics, University of Amsterdam, The Netherlands.
Woonink
F
F
Zuidema
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D002991:Clofazimine / Q000008:administration & dosage* / Q000494:pharmacology; D003622:Dapsone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006207:Half-Life; D006801:Humans; D007918:Leprosy / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009549:Nigeria; D010349:Patient Compliance; D012293:Rifampin / Q000008:administration & dosage* / Q000494:pharmacology
D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin